Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women

Sherene S. Min, Amanda H. Corbett, Naser Rezk, Susan Cu-Uvin, Susan A. Fiscus, Leslie Anne Petch Lee, Myron S. Cohen, Angela D M Kashuba

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.

Original languageEnglish (US)
Pages (from-to)1577-1580
Number of pages4
JournalJournal of Acquired Immune Deficiency Syndromes
Volume37
Issue number5
DOIs
StatePublished - Dec 15 2004
Externally publishedYes

Fingerprint

Reverse Transcriptase Inhibitors
Protease Inhibitors
HIV-1
Pharmacokinetics
Post-Exposure Prophylaxis
Therapeutic Irrigation
HIV
Research
Pharmaceutical Preparations

Keywords

  • Antiretroviral concentration
  • Female genital tract
  • HIV-1
  • Nonnucleoside reverse transcriptase inhibitor
  • Pharmacokinetic
  • Protease inhibitor

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. / Min, Sherene S.; Corbett, Amanda H.; Rezk, Naser; Cu-Uvin, Susan; Fiscus, Susan A.; Petch Lee, Leslie Anne; Cohen, Myron S.; Kashuba, Angela D M.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 37, No. 5, 15.12.2004, p. 1577-1580.

Research output: Contribution to journalArticle

Min, Sherene S. ; Corbett, Amanda H. ; Rezk, Naser ; Cu-Uvin, Susan ; Fiscus, Susan A. ; Petch Lee, Leslie Anne ; Cohen, Myron S. ; Kashuba, Angela D M. / Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. In: Journal of Acquired Immune Deficiency Syndromes. 2004 ; Vol. 37, No. 5. pp. 1577-1580.
@article{40a4e8d188d44f50b9bd59b48729f6f3,
title = "Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women",
abstract = "The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10{\%} to >100{\%} of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.",
keywords = "Antiretroviral concentration, Female genital tract, HIV-1, Nonnucleoside reverse transcriptase inhibitor, Pharmacokinetic, Protease inhibitor",
author = "Min, {Sherene S.} and Corbett, {Amanda H.} and Naser Rezk and Susan Cu-Uvin and Fiscus, {Susan A.} and {Petch Lee}, {Leslie Anne} and Cohen, {Myron S.} and Kashuba, {Angela D M}",
year = "2004",
month = "12",
day = "15",
doi = "10.1097/00126334-200412150-00008",
language = "English (US)",
volume = "37",
pages = "1577--1580",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women

AU - Min, Sherene S.

AU - Corbett, Amanda H.

AU - Rezk, Naser

AU - Cu-Uvin, Susan

AU - Fiscus, Susan A.

AU - Petch Lee, Leslie Anne

AU - Cohen, Myron S.

AU - Kashuba, Angela D M

PY - 2004/12/15

Y1 - 2004/12/15

N2 - The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.

AB - The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.

KW - Antiretroviral concentration

KW - Female genital tract

KW - HIV-1

KW - Nonnucleoside reverse transcriptase inhibitor

KW - Pharmacokinetic

KW - Protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=10644295700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644295700&partnerID=8YFLogxK

U2 - 10.1097/00126334-200412150-00008

DO - 10.1097/00126334-200412150-00008

M3 - Article

VL - 37

SP - 1577

EP - 1580

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -